TAT and ovarian carcinoma: Recently, Sun et al. [54] managed to successfully deliver a GCV-converted HSV-tTK in ovarian cancer cells employing Tat/pDNA/C16TAB (T-P-C) NPs, demonstrating targeted delivery in mouse models with human ovarian cancer.